GSK vs RLI · P/E 13, $103.31B cap vs P/E 24, rev $999.4M
GlaxoSmithKline PLC ADR (GSK) versus RLI Corp (RLI) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
RLI Corp (RLI) is a insurance - property & casualty company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported RLI revenue for 2026-06-30 was $999.4M. Net income was $222.9M. RLI currently screens at market cap $6.58B and trailing P/E 23.7.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. RLI currently screens at market cap $6.58B and trailing P/E 23.7.
Not investment advice. Open the GSK and RLI stock pages for the full models.
Not investment advice.